Amgen Inc.

Abbott Laboratories Corporation

Su-Jen Lai

Jonathan B Houze

Zhihua Ma

Paul John Dransfield

Vatee Pattaropong

Nobuko Nishimura

Julie Anne Heath

David John Kopecky

Mikkel V Debenedetto

Xiaoqi Chen

Zice Fu

Xiaodong Wang

Steven H Olson

Richard V Connors

Gayathri Swaminath

Ning Chen

Alan C Cheng

Aarif Yusuf Khakoo

Yinhong Chen

Julio Cesar Medina

Xiaohui Du

Jeffrey Thomas Mihalic

Wen-Chen Yeh

Jeffrey Deignan

Kevin Chao Yang

Matthew R Kaller

Ted Charles Judd

Daniel B Horne

Simon J Hedley

Lawrence R McGee

James S Harvey

Frank Kayser

Robert P Farrell

Charles Kreiman

Lars V Heumann

Malgorzata Wanska

Philip Dean Ramsden

Ankit Sharma

Andrew J Souers

Philip R Kym

Michael A Patane

Matthew Irvine Brown

Anil Vasudevan

Matthew J LaMarche

Rajesh R Iyengar

Martin P Maguire

Kevin Yang

Mathew M Mulhern

Christopher Blackburn

Courtney A Cullis

Dariusz Wodka

David C Moebius

Ju Gao

John K Lynch

Jennifer C Freeman

James A Brown

Mary Katherin Verzal

Matthew J Lamarche

Jennifer L Che

Julio C Medina

Mary Katherine Verzal

Jeffrey T Mihalic

Jonathan Houze

Ted C Judd

Matthew Brown

James Brown

Lawrence R Mcgee

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Alkyl substituted triazole compounds as agonists of the APJ Receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Triazole phenyl compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein. 

Triazole pyridyl compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

Growing community of inventors

Boston, MA, United States of America

Su-Jen Lai